BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20413709)

  • 1. A BRCA1 promoter variant (rs11655505) and breast cancer risk.
    Verderio P; Pizzamiglio S; Southey MC; Spurdle AB; Hopper JL; Chen X; Beesley J; ; Schmutzler RK; Engel C; Burwinkel B; Bugert P; Ficarazzi F; Manoukian S; Barile M; Wappenschmidt B; Chenevix-Trench G; Radice P; Peterlongo P
    J Med Genet; 2010 Apr; 47(4):268-70. PubMed ID: 20413709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
    Bau DT; Fu YP; Chen ST; Cheng TC; Yu JC; Wu PE; Shen CY
    Cancer Res; 2004 Jul; 64(14):5013-9. PubMed ID: 15256476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?
    Jakubowska A; Jaworska K; Cybulski C; Janicka A; Szymańska-Pasternak J; Lener M; Narod SA; Lubiński J;
    Eur J Cancer; 2009 Mar; 45(5):837-42. PubMed ID: 19071013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study.
    Soucek P; Borovanova T; Pohlreich P; Kleibl Z; Novotny J
    Breast Cancer Res Treat; 2007 Jun; 103(2):219-24. PubMed ID: 17039264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland.
    Jakubowska A; Narod SA; Goldgar DE; Mierzejewski M; Masojć B; Nej K; Huzarska J; Byrski T; Górski B; Lubiński J
    Cancer Epidemiol Biomarkers Prev; 2003 May; 12(5):457-9. PubMed ID: 12750242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
    J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiński J; Scott RJ; Hamann U
    Breast Cancer Res Treat; 2007 Sep; 104(3):299-308. PubMed ID: 17063264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
    Bean GR; Ibarra Drendall C; Goldenberg VK; Baker JC; Troch MM; Paisie C; Wilke LG; Yee L; Marcom PK; Kimler BF; Fabian CJ; Zalles CM; Broadwater G; Scott V; Seewaldt VL
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):50-6. PubMed ID: 17220331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer.
    Hasan TN; Leena Grace B; Shafi G; Syed R
    Clin Transl Oncol; 2013 Jul; 15(7):555-62. PubMed ID: 23263908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
    Freedman ML; Penney KL; Stram DO; Riley S; McKean-Cowdin R; Le Marchand L; Altshuler D; Haiman CA
    Cancer Res; 2005 Aug; 65(16):7516-22. PubMed ID: 16103107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
    Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
    Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A functional promoter polymorphism in the TERT gene does not affect inherited susceptibility to breast cancer.
    Varadi V; Brendle A; Grzybowska E; Johansson R; Enquist K; Butkiewicz D; Pamula-Pilat J; Pekala W; Hemminki K; Lenner P; Försti A
    Cancer Genet Cytogenet; 2009 Apr; 190(2):71-4. PubMed ID: 19380022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.
    Sng JH; Chang J; Feroze F; Rahman N; Tan W; Lim S; Lehnert M; van der Pool S; Wong J
    Br J Cancer; 2000 Feb; 82(3):538-42. PubMed ID: 10682662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.